Advertisement
Global News Hour at 6 Edmonton
December 16 2020 7:47pm

Health Canada approves $2.8M Zolgensma treatment for spinal muscular atrophy

In the past year, we’ve shared the stories of a number of Alberta children seeking Zolgensma — a $2.8 million drug that replaces the dysfunctional gene which causes spinal muscular atrophy Type 1. That life-saving therapy has now been approved by Health Canada. As Morgan Black reports, the news brings renewed hope to families who’ve been tirelessly fundraising to afford the staggering cost.

Video Home